Recent studies have reported a higher incidence of non arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden and permanent vision loss, among some users of semaglutide based drugs
What this means for real people For readers wondering whether the science or the price should sway decisions, here is a practical take by experts - If your goal is diabetes control and modest weight loss, semaglutide formulations (Ozempic) remain a mainstream choice, supported by cardiovascular outcomes data and diabetes approvals
A combination of gastrointestinal side effects, reduced hunger hormones, and early satiety cause you to eat less and therefore, for some*, you lose weight
Each case depends on the specific drug taken, the timeline of symptoms, and how the prescribing physician framed the risks